ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Inhibition of TLR4/TRAF6/NF-κB pathway by empagliflozin mitigates concanavalin A-induced autoimmune hepatitis in mice.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Concanavalin A (ConA) is a commonly used paradigm for inducing autoimmune hepatitis (AIH) in mice. This study was designed to examine the potential prophylactic effect of empagliflozin (Empa) against ConA-induced AIH. Mice received Empa (10 & 25 mg/kg) for 7 days and then injected with ConA (20 mg/kg) on day 7. Empa showed hepatoprotective effects indicated by decreased serum levels of transaminases, alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) and elevated levels of albumin. Additionally, Empa corrected the equilibrium between antioxidants and oxidants, and decreased inflammation; this was demonstrated by the down regulation of expression of toll like receptor 4 (TLR4) and nuclear factor-kappa B (NF-κBp65) besides reduction in hepatic levels of myeloid differentiation primary response 88 (MYD88), tumor necrosis factor-α (TNF-α), TNF Receptor Associated Factor 6 (TRAF6), and interleukin (IL-1)β concomitant with increment in levels of IL10 and hepatic expression of nuclear factor erythroid 2-Related Factor 2 (Nrf2). In addition, Empa improved the histopathological alterations induced by ConA and this was clear in micrographs obtained from transmission electron microscopy. Empa could be a useful candidate to attenuate AIH pending clinical evaluation.
Indexed as
Identifiers
41964671What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.